WO2000042994A3 - Inhibition of bacterial dissemination - Google Patents

Inhibition of bacterial dissemination Download PDF

Info

Publication number
WO2000042994A3
WO2000042994A3 PCT/US2000/001340 US0001340W WO0042994A3 WO 2000042994 A3 WO2000042994 A3 WO 2000042994A3 US 0001340 W US0001340 W US 0001340W WO 0042994 A3 WO0042994 A3 WO 0042994A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
bacterial dissemination
inhibition
peritoneal cavity
dissemination
bacterial
Prior art date
Application number
PCT/US2000/001340
Other languages
French (fr)
Other versions
WO2000042994A2 (en )
Inventor
Sanna M Goyert
Alain Haizot
Jack Silver
Original Assignee
Sanna M Goyert
Alain Haizot
Long Island Jewish Res Inst
Jack Silver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Abstract

Bacterial dissemination is inhibited by administering a substance which accelerates recruitment of neutrophils to the peritoneal cavity and thereby inhibits bacterial dissemination from the peritoneal cavity lipids are of particular interest. Substances are preferably screened in normal and/or CDN deficient mice.
PCT/US2000/001340 1999-01-21 2000-01-21 Inhibition of bacterial dissemination WO2000042994A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11667199 true 1999-01-21 1999-01-21
US60/116,671 1999-01-21

Publications (2)

Publication Number Publication Date
WO2000042994A2 true WO2000042994A2 (en) 2000-07-27
WO2000042994A3 true true WO2000042994A3 (en) 2003-08-28

Family

ID=22368549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001340 WO2000042994A3 (en) 1999-01-21 2000-01-21 Inhibition of bacterial dissemination

Country Status (1)

Country Link
WO (1) WO2000042994A3 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2010141861A1 (en) 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EP2694099A1 (en) 2011-04-08 2014-02-12 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
ES2673556T3 (en) 2012-05-16 2018-06-22 Immune Design Corp. Vaccines for HSV-2
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2018056150A1 (en) * 2016-09-23 2018-03-29 ティーエフケイ株式会社 Compound or salt thereof, anti-inflammatory agent, anticancer agent for lung cancer, method for producing compound or salt thereof, method for treating inflammatory disease, and method for treating lung cancer

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985005555A1 (en) * 1984-05-30 1985-12-19 Baxter Travenol Laboratories, Inc. Dialysis with monophosphoryl lipid a
JPS6168497A (en) * 1984-09-11 1986-04-08 Terumo Corp Sugaralcohol ester derivative and neutrophils activator containing same
GB2220211A (en) * 1988-06-29 1990-01-04 Ribi Immunochem Research Inc Modified lipopolysaccharides
EP0536969A2 (en) * 1991-10-11 1993-04-14 Eisai Co., Ltd. Anti-endotoxin compounds
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
WO1993019087A1 (en) * 1992-03-19 1993-09-30 Emory University School Of Medicine Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of cap37
WO1994021280A1 (en) * 1993-03-22 1994-09-29 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
WO1995003067A1 (en) * 1993-07-21 1995-02-02 Khavinson Vladimir Khatskelevi Pharmaceutical with immunomodulating activity
WO1996008272A1 (en) * 1994-09-16 1996-03-21 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
WO1997000081A1 (en) * 1995-06-19 1997-01-03 Goyert Sanna M A method for inhibiting bacteremia and bacterial dissemination
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
WO2000018411A1 (en) * 1998-09-25 2000-04-06 The Collaborative Group, Ltd. VERY HIGH MOLECULAR WEIGHT β-GLUCANS

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985005555A1 (en) * 1984-05-30 1985-12-19 Baxter Travenol Laboratories, Inc. Dialysis with monophosphoryl lipid a
JPS6168497A (en) * 1984-09-11 1986-04-08 Terumo Corp Sugaralcohol ester derivative and neutrophils activator containing same
GB2220211A (en) * 1988-06-29 1990-01-04 Ribi Immunochem Research Inc Modified lipopolysaccharides
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
EP0536969A2 (en) * 1991-10-11 1993-04-14 Eisai Co., Ltd. Anti-endotoxin compounds
WO1993019087A1 (en) * 1992-03-19 1993-09-30 Emory University School Of Medicine Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of cap37
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
WO1994021280A1 (en) * 1993-03-22 1994-09-29 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
WO1995003067A1 (en) * 1993-07-21 1995-02-02 Khavinson Vladimir Khatskelevi Pharmaceutical with immunomodulating activity
WO1996008272A1 (en) * 1994-09-16 1996-03-21 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
WO1997000081A1 (en) * 1995-06-19 1997-01-03 Goyert Sanna M A method for inhibiting bacteremia and bacterial dissemination
WO2000018411A1 (en) * 1998-09-25 2000-04-06 The Collaborative Group, Ltd. VERY HIGH MOLECULAR WEIGHT β-GLUCANS

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PATHOLOGY. UNITED STATES NOV 1987, vol. 129, no. 2, November 1987 (1987-11-01), pages 217 - 222, ISSN: 0002-9440 *
BARSIG J ET AL: "CONTROL OF FECAL PERITONEAL INFECTION IN MICE BY COLONY-STIMULATINGFACTORS", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 174, no. 4, October 1996 (1996-10-01), pages 790 - 799, XP000956403, ISSN: 0022-1899 *
BLEIGERG I ET AL: "ENHANCED RESISTANCE OF BONE MARROW TRANSPLANTED MICE TO BACTERIAL INFECTION INDUCED BY RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 75, no. 6, 15 March 1990 (1990-03-15), pages 1262 - 1266, XP000956324, ISSN: 0006-4971 *
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 83, no. 2, 1991, pages 231 - 236, ISSN: 0009-9104 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991, APPLEBERG R ET AL: "HOST AND BACTERIAL FACTORS CONTROL THE MYCOBACTERIUM-AVIUM INDUCED CHRONIC PERITONEAL GRANULOCYTOSIS IN MICE", XP002243380, Database accession no. PREV199191097011 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1991, MATSUMOTO M ET AL: "Mechanism of protective effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on Pseudomonas infection.", XP002243381, Database accession no. NLM1717812 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 1999 (1999-02-01), MERCER-JONES M A ET AL: "Regulation of early peritoneal neutrophil migration by macrophage inflammatory protein-2 and mast cells in experimental peritonitis.", XP002243384, Database accession no. NLM10088608 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 1995 (1995-05-01), GAHAN C G ET AL: "Non-dystrophic 129 REJ mice are susceptible to i.p. infection with Listeria monocytogenes despite an ability to recruit inflammatory neutrophils to the peritoneal cavity.", XP002243383, Database accession no. NLM7476100 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 1996 (1996-05-01), WIKTOR-JEDRZEJCZAK W ET AL: "Colony-stimulating factor 1-dependent resident macrophages play a regulatory role in fighting Escherichia coli fecal peritonitis.", XP002243382, Database accession no. NLM8613363 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 1987 (1987-11-01), KRAUSE P J ET AL: "Pentoxifylline enhancement of defective neutrophil function and host defense in neonatal mice.", XP002243379, Database accession no. NLM3674202 *
DATABASE WPI Week 198620, Derwent World Patents Index; AN 1986-129489, XP002243385 *
DESOUZA I A ET AL: "RESIDENT MACROPHAGES MODULATE THE NEUTROPHIL MIGRATION INDUCED BY STAPHYLOCOCCAL ENTEROTOXIN B INTO THE MOUSE PERITONEAL CAVITY", JOURNAL OF NATURAL TOXINS, COLLINS, CO, US, vol. 5, no. 3, 1996, pages 341 - 350, XP000956360, ISSN: 1058-8108 *
HAZIOT A ET AL: "RESISTANCE TO ENDOTOXIN SHOCK AND REDUCED DISSEMINATION OF GRAM- NEGATIVE BACTERIA IN CD14-DEFICIENT MICE", IMMUNITY, CELL PRESS, US, vol. 4, no. 4, 1 April 1996 (1996-04-01), pages 407 - 414, XP000608215, ISSN: 1074-7613 *
INFECTION AND IMMUNITY. UNITED STATES MAY 1996, vol. 64, no. 5, May 1996 (1996-05-01), pages 1577 - 1581, ISSN: 0019-9567 *
ISHIKURA H ET AL: "ACTIVATION OF NEUTROPHIL FUNCTION BY RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR IMPROVES THE SURVIVAL OF RATS WITH PERITONITIS", SURGERY TODAY, XX, XX, vol. 26, no. 9, 1996, pages 694 - 699, XP000956275 *
JOURNAL OF LEUKOCYTE BIOLOGY. UNITED STATES FEB 1999, vol. 65, no. 2, February 1999 (1999-02-01), pages 249 - 255, ISSN: 0741-5400 *
KARLSSON A ET AL: "MYCOBACTERIAL LIPOARABINOMANNANS PRIME HUMAN NEUTROPHILS", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. suppl., June 1999 (1999-06-01), pages 109, XP000957400, ISSN: 0741-5400 *
KLAERNER H G ET AL: "IMMUNIZATION WITH ANTIBODIES THAT MIMIC LPS PROTECTS AGAINST GRAM NEGATIVE BACTERIAL SEPSIS", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 69, no. 2, 1997, pages 249 - 254, XP000956236, ISSN: 0022-4804 *
LYNN W A ET AL: "LIPOPOLYSACCHARIDE-INDUCED STIMULATION OF CD11B/CD18 EXPRESSION ON NEUTROPHILS. EVIDENCE OF SPECIFIC RECEPTOR-BASED RESPONSE AND INHIBITION BY LIPID A-BASED ANTAGONISTS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 147, no. 9, 1 November 1991 (1991-11-01), pages 3072 - 3079, XP002027445, ISSN: 0022-1767 *
MICROBIAL PATHOGENESIS. ENGLAND MAY 1995, vol. 18, no. 5, May 1995 (1995-05-01), pages 355 - 364, ISSN: 0882-4010 *
MICROBIOLOGY AND IMMUNOLOGY. JAPAN 1991, vol. 35, no. 6, 1991, pages 461 - 474, ISSN: 0385-5600 *
NAKANO Y ET AL: "PROTECTIVE EFFECT OF RECOMBINANT TUMOR NECROSIS FACTOR-ALPHA IN MURINE SALMONELLOSIS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 144, no. 5, 1 March 1990 (1990-03-01), pages 1935 - 1941, XP000946975, ISSN: 0022-1767 *
RASMUSSEN L-T ET AL: "NOVEL IMMUNOMODULATORS WITH PRONOUNCED IN VIVO EFFECTS CAUSED BY STIMULATION OF CYTOKINE RELEASE", JOURNAL OF CELLULAR BIOCHEMISTRY, LISS, NEW YORK, NY, US, vol. 46, no. 1, 1991, pages 60 - 68, XP000956282, ISSN: 0730-2312 *
RIBEIRO R A ET AL: "RECOMCINANT GAMM INTERFERON CAUSES NEUTROPHIL MIGRATION MEDIATED BY THE RELEASE OF A MACROPHAGE NEUTROPHIL CHEMOTACTIC FACTOR", JOURNAL OF EXPERIMENTAL PATHOLOGY, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 71, no. 5, 1990, pages 717 - 725, XP000956404, ISSN: 0730-8485 *
ROACH T I A ET AL: "MACROPHAGE ACTIVATION: LIPOARABINOMANNAN FROM AVIRULENT AND VIRULENT STRAINS OF MYCOBACTERIUM TUBERCULOSIS DIFFERENTIALLY INDUCES THE EARLY GENES C-FOS, KC, JE, AND TUMOR NECROSIS FACTOR-ALPHA1", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 150, no. 5, 1 March 1993 (1993-03-01), pages 1886 - 1896, XP000952838, ISSN: 0022-1767 *
SHOZO KOTANI: "SYNTHETIC LIPID A WITH ENDOTOXIC AND RELATED BIOLOGICAL ACTIVITIES COMPARABLE TO THOSE OF A NATURAL LIPID A FROM AN ESCHERICHIA COLI RE-MUTANT", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 49, no. 1, 1 July 1985 (1985-07-01), pages 225 - 237, XP000378696, ISSN: 0019-9567 *
STEVENS P ET AL: "INTERLEUKIN-2 INCREASES THE OXIDATIVE ACTIVITY AND INDUCES MIGRATION OF MURINE POLYMORPHONUCLEAR LEUKOCYTES IN VIVO", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 12, no. 6, 1990, pages 605 - 611, XP000956332, ISSN: 0192-0561 *
TAKADA H ET AL: "IMMUNOPHARMACOLOGICAL ACTIVITIES OF A SYNTHETIC COUNTERPART OF A BIOSYNTHETIC LIPID A PRECURSOR MOLECULE AND OF ITS ANALOGS", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 48, no. 1, April 1985 (1985-04-01), pages 219 - 227, XP000946980, ISSN: 0019-9567 *
TERLIKOWSKI S ET AL: "A COMPARISON OF THE PERITONEAL CELL POPULATION OF PREGNANT RABBITS AFTER LPS OR TNF-ALPHA INDUCED SEPTIC SHOCK", ROCZNIKI AKADEMII MEDYCZNEJ W BIAOYMSTOKU, MEDICAL ACADEMY OF BIAYSTOK, BIAYSTOK,, PL, vol. 42, no. SUPPL 2, 1997, pages 111 - 119, XP000957465, ISSN: 0067-6489 *
VUOPIO-VARKILA J ET AL: "LIPOPOLYSACCHARIDE-INDUCED NON-SPECIFIF RESISTANCE TO SYSTEMIC ESCHERICHIA COLI INFECTION IN MICE", JOURNAL OF MEDICAL MICROBIOLOGY, HARLOW, GB, vol. 25, no. 3, 1988, pages 197 - 203, XP000956333, ISSN: 0022-2615 *
WOLTMANN A ET AL: "REDUCED BACTERIAL DISSEMINATION AND LIVER INJURY IN CD14-DEFICIENT MICE FOLLOWING A CHRONIC ABSCESS-FORMING PERITONITIS INDUCED BY BACTEROIDES FRAGILIS", MEDICAL MICROBIOLOGY AND IMMUNOLOGY, BERLIN, DE, vol. 187, no. 3, 1999, pages 149 - 156, XP000956323 *

Also Published As

Publication number Publication date Type
WO2000042994A2 (en) 2000-07-27 application

Similar Documents

Publication Publication Date Title
CA2551231A1 (en) Method for the production of an administration form which is secured against misuse
Li et al. Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction
Jeon et al. Activation of NF-κB/Rel in angelan-stimulated macrophages
CA2227272A1 (en) Use of lipids as aids in the production of solid drug forms by melt extrusion
Shallom et al. Altered synaptosomal ATPase activity in rat brain following prolonged in vivo treatment with nicotine
JPS62138418A (en) Shampoo composition
DE20010297U1 (en) Enzyme-mediated modification of fibrin to tissue manipulation: fibrin formulations with peptides
Shi et al. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment
USD436697S1 (en) Round pet bed
JPH04288017A (en) Treating agent for pimple
DE20207569U1 (en) Dietary and pharmaceutical compositions
JPS6283877A (en) Inhibitor of growth and proliferation of bacteria
DE20116428U1 (en) Pharmaceutical compositions comprising amlodipine maleate
USD436363S1 (en) Decorative shielding for combine harvester
DE20013873U1 (en) Arrangement for the selective display of two-dimensional or three-dimensionally perceivable image content
USD431486S (en) Personal alarm system
DE20305646U1 (en) Training wall for footballers to practice ball return skills has 7 right-angled wall sections that have longitudinal side edges with quadratic wall parts and are connected via stumps to each other
WO1996021468A3 (en) Chemically modified interferon
Cornelissen et al. Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B
JPH03183457A (en) Functional food
WO2000007979A3 (en) Compounds and compositions for delivering active agents
USD456635S1 (en) Demonstration and exhibition stand for a window product and marketing materials
JPS6410985A (en) Glucosyltransferase inhibitor
DE29919083U1 (en) upholstered furniture
DE20007958U1 (en) furniture body

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase